Sirio Pharma (300791) — Capital Reinvestment Ratio
Latest as of June 2023:
0.59x
Sirio Pharma (300791) has a Capital Reinvestment Ratio of 0.59x as of June 2023, meaning it reinvests 1% of its operating cash flow (CN¥101.61 Million) in capital expenditures (CN¥59.65 Million). See 300791 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.59x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥101.61 Million
CNY
Capital Expenditures
CN¥59.65 Million
CNY
Data as of
Jun 2023
Most recent filing
Sirio Pharma Capital Reinvestment Ratio (2017–2024)
This chart tracks Sirio Pharma's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Sirio Pharma (2017–2024)
Year-by-year Capital Reinvestment Ratio for Sirio Pharma from 2017 to 2024. For live market cap and broader valuation context, see Sirio Pharma (300791) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.73x | CN¥566.97 Million | CN¥412.13 Million | ▼ -37.9% |
| 2023 | 1.17x | CN¥386.08 Million | CN¥451.70 Million | ▲ +77.2% |
| 2022 | 0.66x | CN¥444.86 Million | CN¥293.69 Million | ▼ -57.0% |
| 2021 | 1.54x | CN¥341.38 Million | CN¥524.68 Million | ▲ +120.1% |
| 2020 | 0.70x | CN¥319.57 Million | CN¥223.14 Million | ▼ -3.1% |
| 2019 | 0.72x | CN¥231.60 Million | CN¥166.90 Million | ▼ -44.8% |
| 2018 | 1.30x | CN¥183.46 Million | CN¥239.32 Million | ▼ -59.7% |
| 2017 | 3.24x | CN¥49.35 Million | CN¥159.82 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow